{
  "personality": null,
  "timestamp": "2025-11-10T04:39:20.403040",
  "category": "Health",
  "news_summary": "Advancements in medical research are revolutionizing cancer treatment, improving drug effectiveness prediction, preventing dangerous reactions, and harnessing DNA's potential to enhance medicine development.",
  "news_summary_fr": "Les progrès de la recherche médicale révolutionnent le traitement du cancer, améliorent la prédiction de l'efficacité des médicaments, préviennent les réactions dangereuses et exploitent le potentiel de l'ADN pour améliorer le développement des médicaments.",
  "news_summary_es": "Los avances en investigación médica están revolucionando el tratamiento del cáncer, mejorando la predicción de la eficacia de los fármacos, previniendo reacciones peligrosas y aprovechando el potencial del ADN para mejorar el desarrollo de medicamentos.",
  "articles": [
    {
      "title": "New bacterial therapy destroys cancer without the immune system",
      "summary": "A Japanese-led research team has developed AUN, a groundbreaking immune-independent bacterial cancer therapy that uses two harmonized bacteria to destroy tumors even in patients with weakened immune systems. By leveraging the natural synergy between Proteus mirabilis and Rhodopseudomonas palustris, AUN selectively targets cancer cells, reshapes itself within tumors, and avoids harmful side effects like cytokine release syndrome.",
      "content": "A research team led by Professor Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST), in collaboration with Daiichi Sankyo Co., Ltd. and the University of Tsukuba, has created an innovative cancer treatment that works without relying on the immune system. The new approach uses a unique microbial partnership known as AUN, forming the foundation of an immune-independent bacterial therapy.\n\nThe concept of bacterial cancer therapy dates back to 1868, when German physician Busch reported that a cancer patient deliberately infected with bacteria later experienced remission. In 1893, Dr. William Coley further advanced this idea by developing bacterial-based treatments, paving the way for modern immunotherapies such as checkpoint inhibitors and CAR-T cell therapies.\n\nWhile these treatments have transformed cancer care, they share a major drawback: they depend heavily on the immune system. For patients whose immunity is weakened by chemotherapy or radiotherapy, such therapies often fail to work effectively.\n\nAUN: Two Bacteria in Perfect Balance\n\nThe newly developed AUN therapy directly overcomes this limitation. It is made up of two naturally occurring bacterial species:\n\nProteus mirabilis (A-gyo), a bacterium that naturally resides in tumors\n\nRhodopseudomonas palustris (UN-gyo), a photosynthetic bacterium\n\nTogether, these bacteria act in harmony to destroy cancer cells in both animal and human models. Remarkably, they succeed even when immune function is impaired. AUN has shown strong compatibility with the human body and few side effects, including suppression of cytokine release syndrome (CRS), a potentially dangerous immune reaction.\n\nHow AUN Works to Eliminate Tumors\n\nThe AUN consortium achieves its tumor-fighting power through a series of coordinated mechanisms:\n\nPrecisely targeting and destroying tumor blood vessels and cancer cells\n\nUndergoing a structural transformation in A-gyo (filamentation) triggered by tumor-specific metabolites, which enhances its ability to kill cancer cells\n\nAdjusting the bacterial ratio inside the tumor environment, shifting from an initial mix of roughly 3:97 (A-gyo to UN-gyo) to about 99:1, maximizing its therapeutic strength\n\nReducing toxicity and minimizing side effects, including avoidance of CRS\n\nHarmony Between Opposites\n\nUN-gyo only becomes active and beneficial when paired with A-gyo, serving as a regulator that curbs harmful bacterial activity while increasing their cancer-killing precision. This mutual cooperation embodies the Japanese concept of \"AUN,\" symbolizing balance and harmony between opposites. It is this finely tuned relationship that gives the therapy its exceptional results, achieving what traditional immune-dependent treatments could not.\n\nToward Clinical Trials and a New Era in Cancer Therapy\n\n\"We are preparing to launch a startup to advance this technology and hope to begin clinical trials within six years,\" explained Professor Miyako. \"A new chapter in bacteria-based cancer therapy -- pursued for over 150 years -- is finally beginning.\"\n\nThis groundbreaking method marks a turning point for cancer patients with weakened immune systems. It offers a long-sought option where conventional immunotherapies fall short, signaling the arrival of truly immune-independent cancer treatment.\n\nThe findings have been published in Nature Biomedical Engineering.",
      "url": "https://www.sciencedaily.com/releases/2025/11/251109013250.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-11-10",
      "sentiment_score": 0.95,
      "reasoning": "The article reports a significant breakthrough in cancer therapy with the development of an immune-independent bacterial treatment that can destroy tumors even in patients with weakened immune systems. This innovation has broad implications for cancer patients worldwide, especially those who cannot benefit from current immunotherapies. The article provides detailed context on the therapy's mechanism, historical background, and future clinical plans, demonstrating substantial real-world impact and significance.",
      "category": "Health",
      "personality_title": "New bacterial therapy kills cancer without needing the immune system",
      "personality_presentation": "**Context** – Scientists have long tried using bacteria to fight cancer, starting in the 1800s. Modern treatments often depend on a strong immune system, which not all patients have, especially after chemotherapy or radiation.\n\n**What happened** – A team in Japan led by Professor Eijiro Miyako created a new therapy called AUN. It uses two types of bacteria working together—Proteus mirabilis and Rhodopseudomonas palustris—to attack tumors directly. This therapy works even when the immune system is weak and avoids dangerous side effects.\n\n**Impact** – AUN is unique because it does not rely on the immune system to fight cancer, making it helpful for patients who cannot use current immunotherapies. The two bacteria balance each other, targeting cancer cells precisely and changing inside tumors to become more effective. This reduces harm to the body and avoids immune reactions that can be risky.\n\n**What's next step** – The research team plans to start clinical trials in about six years and is preparing a startup company to develop this treatment further. If successful, AUN could become a new option for many cancer patients worldwide.\n\n**One-sentence takeaway** – A new bacterial therapy called AUN offers a promising way to destroy cancer even when the immune system is weak, opening doors to treatments for more patients.",
      "personality_title_fr": "Une nouvelle thérapie bactérienne détruit le cancer sans dépendre du système immunitaire",
      "personality_presentation_fr": "**Contexte** – Depuis les années 1800, les scientifiques essaient d’utiliser des bactéries pour combattre le cancer. Les traitements modernes nécessitent souvent un système immunitaire fort, ce qui n’est pas le cas de tous les patients, surtout après une chimiothérapie ou une radiothérapie.\n\n**Ce qui s’est passé** – Une équipe japonaise dirigée par le professeur Eijiro Miyako a créé une nouvelle thérapie appelée AUN. Elle utilise deux types de bactéries travaillant ensemble—Proteus mirabilis et Rhodopseudomonas palustris—pour attaquer directement les tumeurs. Cette thérapie fonctionne même quand le système immunitaire est faible et évite des effets secondaires dangereux.\n\n**Impact** – AUN est unique car elle ne dépend pas du système immunitaire pour lutter contre le cancer, ce qui la rend utile pour les patients qui ne peuvent pas utiliser les immunothérapies actuelles. Les deux bactéries s’équilibrent, ciblent précisément les cellules cancéreuses et changent à l’intérieur des tumeurs pour être plus efficaces. Cela réduit les dommages au corps et évite des réactions immunitaires risquées.\n\n**Prochaine étape** – L’équipe de recherche prévoit de commencer des essais cliniques dans environ six ans et prépare une startup pour développer davantage ce traitement. Si cela réussit, AUN pourrait devenir une nouvelle option pour de nombreux patients atteints de cancer dans le monde.\n\n**Phrase clé** – Une nouvelle thérapie bactérienne appelée AUN offre une manière prometteuse de détruire le cancer même quand le système immunitaire est faible, ouvrant la voie à des traitements pour plus de patients.",
      "personality_title_es": "Nueva terapia bacteriana destruye el cáncer sin necesitar el sistema inmunológico",
      "personality_presentation_es": "**Contexto** – Desde el siglo XIX, los científicos han intentado usar bacterias para combatir el cáncer. Los tratamientos actuales a menudo necesitan un sistema inmunológico fuerte, que no todos los pacientes tienen, especialmente después de quimioterapia o radioterapia.\n\n**Qué pasó** – Un equipo japonés liderado por el profesor Eijiro Miyako creó una nueva terapia llamada AUN. Usa dos tipos de bacterias que trabajan juntas—Proteus mirabilis y Rhodopseudomonas palustris—para atacar directamente los tumores. Esta terapia funciona incluso cuando el sistema inmunológico está débil y evita efectos secundarios peligrosos.\n\n**Impacto** – AUN es única porque no depende del sistema inmunológico para combatir el cáncer, lo que la hace útil para pacientes que no pueden usar las inmunoterapias actuales. Las dos bacterias se equilibran, apuntan con precisión a las células cancerosas y cambian dentro de los tumores para ser más efectivas. Esto reduce el daño al cuerpo y evita reacciones inmunes riesgosas.\n\n**Próximo paso** – El equipo planea comenzar ensayos clínicos en unos seis años y está preparando una startup para desarrollar más este tratamiento. Si tiene éxito, AUN podría ser una nueva opción para muchos pacientes con cáncer en todo el mundo.\n\n**Frase clave** – Una nueva terapia bacteriana llamada AUN ofrece una forma prometedora de destruir el cáncer incluso cuando el sistema inmunológico está débil, abriendo puertas a tratamientos para más pacientes.",
      "image_url": "public/images/news_image_New-bacterial-therapy-destroys-cancer-without-the-.png",
      "image_prompt": "Two distinct but harmoniously intertwined bacteria—one shaped like a delicate filamentous strand glowing softly with warm amber tones, the other a gentle, radiant purple sphere with subtle light reflections—cooperatively encircle and gently dismantle a stylized, semi-transparent tumor mass depicted as a muted gray organic form, all set against a soft, natural beige background that evokes balance and healing."
    },
    {
      "title": "New online tool can predict how well blood pressure drugs will work",
      "summary": "A new blood pressure calculator built on extensive clinical trial data helps doctors accurately estimate how much each medication will reduce blood pressure. The tool simplifies complex treatment choices and replaces unreliable BP measurements with solid evidence.",
      "content": "A groundbreaking Blood Pressure Treatment Efficacy Calculator, developed using data from nearly 500 randomized clinical trials involving more than 100,000 participants, now enables doctors to estimate how much different medications can lower a patient's blood pressure.\n\nRecently published in The Lancet, the research behind this tool could transform how high blood pressure is managed. It allows doctors to tailor therapy to each patient's needs based on how much they need to reduce their blood pressure.\n\n\"This is really important because every 1mmHg reduction in systolic blood pressure lowers your risk of heart attack or stroke by two percent,\" said Nelson Wang, cardiologist and Research Fellow at The George Institute for Global Health.\n\n\"But with dozens of drugs, multiple doses per drug, and most patients needing two or more drugs, there are literally thousands of possible options, and no easy way to work out how effective they are,\" he said.\n\nTurning Data Into Smarter Treatment Choices\n\nThe new calculator addresses this complexity by analyzing average treatment effects across hundreds of studies. It also classifies therapies as low, moderate, or high intensity, depending on how much they reduce blood pressure (BP) -- an approach already used in cholesterol management.\n\nA single blood pressure medication, which is still the standard way most treatments begin, typically lowers systolic BP by only 8-9 mmHg. Many patients, however, need drops of 15-30 mmHg to reach healthy targets.\n\nDr. Wang explained that although doctors have traditionally adjusted therapy by monitoring each patient's blood pressure readings, those measurements are too variable to depend on alone.\n\nThe Problem With \"Noisy\" Blood Pressure Readings\n\n\"Blood pressure changes from moment to moment, day to day and by season -- these random fluctuations can easily be as big or larger than the changes brought about by treatment,\" he said.\n\n\"Also, measurement practices are often not perfect, bringing in an additional source of uncertainty -- this means it's very hard to reliably assess how well a medicine is working just by taking repeated measurements.\"\n\nAnthony Rodgers, Senior Professorial Fellow at The George Institute for Global Health, noted that while high blood pressure is the most common reason people visit their doctor, there has never been a single, comprehensive source showing how effective different drugs are, particularly when combined or used at different doses.\n\nA New Approach to Managing Hypertension\n\n\"Using the calculator challenges the traditional 'start low, go slow, measure and judge' approach to treatment, which comes with the high probability of being misled by BP readings, inertia setting in or the burden on patients being too much,\" he said.\n\n\"With this new method you specify how much you need to lower blood pressure, choose an ideal treatment plan to achieve that based on the evidence, and get the patient started on that ideally sooner rather than later.\"\n\nThe next step will be to test this approach in a clinical trial, where treatments are prescribed according to how much a patient needs to lower their blood pressure, using the calculator as a guide.\n\nA Global Health Challenge\n\nHigh blood pressure remains one of the world's most serious health threats, affecting an estimated 1.3 billion people and contributing to about ten million deaths every year.1\n\nOften referred to as a \"silent killer\" because it produces no obvious symptoms, hypertension can go unnoticed until it leads to heart attack, stroke, or kidney disease. Fewer than one in five people with the condition have it adequately controlled.2\n\n\"Given the enormous scale of this challenge, even modest improvements will have a large public health impact -- increasing the percentage of people whose hypertension is under control globally to just 50% could save many millions of lives,\" Professor Rodgers said.\n\nThe Blood Pressure Treatment Efficacy Calculator is freely available at www.bpmodel.org.\n\nNotes",
      "url": "https://www.sciencedaily.com/releases/2025/11/251109013248.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-11-10",
      "sentiment_score": 0.9,
      "reasoning": "The article reports on a new, evidence-based blood pressure treatment efficacy calculator developed from extensive clinical trial data that can help doctors tailor hypertension treatment more accurately. This innovation addresses a major global health challenge affecting over a billion people and has the potential to significantly reduce heart attacks and strokes by improving blood pressure control worldwide. The tool is grounded in solid research, published in a reputable journal, and offers a scalable, practical solution with broad public health impact.",
      "category": "Health",
      "personality_title": "New online tool helps doctors predict how well blood pressure medicines work",
      "personality_presentation": "**Context** – High blood pressure affects about 1.3 billion people worldwide and is a leading cause of heart attacks and strokes. Treating it is complicated because many medicines and doses exist, and blood pressure readings can change a lot from day to day.\n\n**What happened** – Scientists created an online Blood Pressure Treatment Efficacy Calculator using data from nearly 500 clinical trials with over 100,000 patients. This tool helps doctors predict how much different blood pressure medicines will lower a patient’s blood pressure, making it easier to choose the best treatment.\n\n**Impact** – The calculator provides clear estimates based on strong evidence, replacing the usual guesswork from fluctuating blood pressure readings. This means doctors can pick the right medicines faster and more accurately, which is important because even a small drop in blood pressure reduces the risk of heart problems.\n\n**What's next step** – Researchers plan to test this calculator in real medical settings to see how well it helps doctors treat patients. If successful, it could change how blood pressure is managed around the world.\n\n**One-sentence takeaway** – A new calculator uses large-scale research data to help doctors choose the most effective blood pressure medicines for each patient, aiming to improve treatment results worldwide.",
      "personality_title_fr": "Un nouvel outil en ligne aide les médecins à prédire l'efficacité des médicaments contre l'hypertension",
      "personality_presentation_fr": "**Contexte** – L'hypertension touche environ 1,3 milliard de personnes dans le monde et cause de nombreux infarctus et AVC. Le traitement est compliqué car il existe de nombreux médicaments et doses, et la tension artérielle varie beaucoup d'un jour à l'autre.\n\n**Ce qui s’est passé** – Des chercheurs ont créé un calculateur en ligne d'efficacité des traitements contre l'hypertension, basé sur près de 500 essais cliniques rassemblant plus de 100 000 patients. Cet outil aide les médecins à prévoir de combien chaque médicament peut faire baisser la tension, facilitant ainsi le choix du meilleur traitement.\n\n**Impact** – Ce calculateur fournit des estimations claires basées sur des preuves solides, remplaçant les mesures de tension souvent variables. Cela permet aux médecins de choisir plus rapidement et précisément les bons médicaments, ce qui est important car une petite baisse de la tension réduit le risque de problèmes cardiaques.\n\n**Prochaine étape** – Les chercheurs vont tester cet outil dans des hôpitaux pour vérifier son efficacité dans la pratique. S’il fonctionne bien, il pourrait changer la façon dont on traite l’hypertension dans le monde.\n\n**Résumé en une phrase** – Un nouveau calculateur utilise des données de recherche à grande échelle pour aider les médecins à choisir les médicaments contre l’hypertension les plus efficaces pour chaque patient, dans le but d’améliorer les traitements partout dans le monde.",
      "personality_title_es": "Nueva herramienta en línea ayuda a médicos a predecir la eficacia de medicamentos para la presión arterial",
      "personality_presentation_es": "**Contexto** – La presión arterial alta afecta a unos 1.300 millones de personas en todo el mundo y es una causa principal de ataques cardíacos y accidentes cerebrovasculares. Su tratamiento es complicado porque hay muchos medicamentos y dosis, y la presión arterial varía mucho día a día.\n\n**Qué pasó** – Científicos crearon una calculadora en línea de eficacia para el tratamiento de la presión arterial, usando datos de casi 500 ensayos clínicos con más de 100,000 pacientes. Esta herramienta ayuda a los médicos a predecir cuánto puede bajar la presión cada medicamento, facilitando la elección del mejor tratamiento.\n\n**Impacto** – La calculadora ofrece estimaciones claras basadas en evidencia sólida, reemplazando las mediciones de presión arterial que suelen ser variables. Esto permite a los médicos elegir los medicamentos correctos más rápido y con mayor precisión, algo importante porque una pequeña reducción en la presión disminuye el riesgo de problemas cardíacos.\n\n**Próximo paso** – Los investigadores planean probar esta calculadora en hospitales para ver qué tan bien ayuda a tratar a los pacientes. Si funciona, podría cambiar la forma en que se maneja la presión arterial en todo el mundo.\n\n**Resumen en una frase** – Una nueva calculadora usa datos de investigaciones a gran escala para ayudar a los médicos a elegir los medicamentos para la presión arterial más efectivos para cada paciente, con el objetivo de mejorar los tratamientos globalmente.",
      "image_url": "public/images/news_image_New-online-tool-can-predict-how-well-blood-pressur.png",
      "image_prompt": "A detailed, warm-toned painting of a balanced scale with stylized blood pressure monitors and medicine bottles on each side, connected by glowing data streams and graphs flowing between them, set against a soft abstract background symbolizing health and precision."
    },
    {
      "title": "Doctors found a way to stop a deadly metformin reaction",
      "summary": "A hospital in Thailand created a quick-action dialysis protocol for patients with metformin-associated lactic acidosis, a dangerous reaction to a common diabetes drug. The program sharply reduced deaths and sped up treatment times. Awareness also soared, showing how organized emergency pathways can transform patient outcomes.",
      "content": "Metformin-associated lactic acidosis (MALA) is an uncommon but potentially life-threatening complication linked to the diabetes medication metformin. The condition occurs when excessive lactic acid builds up in the body, leading to dangerous changes in blood chemistry. Researchers developed and evaluated a clinical protocol aimed at improving how MALA is recognized and treated. Their findings were presented at ASN Kidney Week 2025.\n\nThe protocol emphasized the immediate start of dialysis as soon as MALA was identified, using one of three methods: intermittent hemodialysis, continuous kidney replacement therapy, or peritoneal dialysis. The program was introduced at Maharat Nakhonratchasima Hospital (MNRH) in Thailand, while Burirum Hospital (BH) served as a comparison site and continued standard care without the new approach.\n\nOver a five-year study period, the researchers analyzed 347 total cases (70 at MNRH before the protocol, 129 after the protocol, and 148 at BH).\n\nMajor Reductions in Deaths and Faster Treatment\n\nResults showed striking improvements at Maharat Nakhonratchasima Hospital. The 30-day death rate fell from 25.7% before the new system to 13.9% afterward. At Burirum Hospital, which did not adopt the protocol, mortality rates remained unchanged (27.2% and 30%).\n\nThe ongoing data at MNRH showed a steady decline in deaths, dropping by 2.08% per quarter throughout the intervention period. Average \"door-to-dialysis\" time -- the time between a patient's hospital admission and the start of dialysis -- was shortened from 870 minutes to 690 minutes. Awareness of MALA among medical staff also rose dramatically, from 38.5% to 89.9% after implementation.\n\nFaster Response, Greater Awareness, and Better Outcomes\n\n\"A standardized MALA protocol covering diagnosis, access, and treatment shortened door-to-dialysis time, increased awareness, and reduced care variation,\" said corresponding author Watanyu Parapiboon, MD, of Maharat Nakhon Ratchasima Hospital in Thailand. \"Fast-track dialysis pathways should be adopted for time-sensitive conditions like MALA. Availability of all dialysis modalities ensures flexibility and enables timely treatment initiation.\"\n\nStudy: \"Reducing Mortality in Metformin-Associated Lactic Acidosis (MALA) Through a Fast-Track Clinical Pathway: A Controlled Interrupted Time Series Quality Improvement Study.\"\n\nMetformin Overview\n\nMetformin is one of the most commonly prescribed medications for managing type 2 diabetes. It works by improving the body's sensitivity to insulin, reducing the amount of glucose produced by the liver, and enhancing glucose uptake by muscle cells. The drug is well established for its effectiveness, affordability, and relatively low risk of causing low blood sugar. Beyond diabetes control, research has explored metformin's potential benefits in weight management, heart health, and even aging, although its primary role remains in helping people with type 2 diabetes maintain stable blood sugar levels.\n\nMetformin-Associated Lactic Acidosis Overview\n\nMetformin-associated lactic acidosis (MALA) is a rare but serious medical emergency in which lactic acid accumulates in the bloodstream due to the body's impaired ability to clear it while taking metformin. This condition can lead to dangerously low blood pH, muscle weakness, rapid breathing, confusion, and in severe cases, organ failure or death. MALA typically occurs in patients with underlying kidney problems, liver disease, or conditions that limit oxygen delivery to tissues. While extremely uncommon, it requires urgent diagnosis and immediate treatment -- often including dialysis -- to remove excess acid and prevent life-threatening complications.",
      "url": "https://www.sciencedaily.com/releases/2025/11/251109013244.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-11-09",
      "sentiment_score": 0.9,
      "reasoning": "The article reports a significant medical breakthrough in treating a rare but deadly complication of a widely used diabetes drug, metformin. The new dialysis protocol implemented in a Thai hospital substantially reduced mortality rates and treatment times, demonstrating a clear positive real-world impact on patient outcomes. The study is well-detailed, showing broad significance for diabetic patients worldwide and emphasizing improved emergency care pathways.",
      "category": "Health",
      "personality_title": "New dialysis protocol cuts deaths from dangerous metformin reaction",
      "personality_presentation": "**Context** – Metformin is a common medicine used to treat type 2 diabetes. Rarely, it can cause a serious problem called metformin-associated lactic acidosis (MALA), where too much acid builds up in the body. This condition can be life-threatening and needs quick treatment.\n\n**What happened** – A hospital in Thailand called Maharat Nakhonratchasima Hospital (MNRH) created a new plan to quickly start dialysis, a treatment that removes harmful acid from the blood, as soon as MALA is diagnosed. They tested this system over five years and compared results with another hospital that did not use the new plan.\n\n**Impact** – The new plan cut the death rate from MALA nearly in half at MNRH, dropping from about 26% to 14%. Treatment started faster, with the time from hospital arrival to dialysis reduced by nearly three hours. Doctors and nurses also became much better at recognizing MALA, which helped save more lives.\n\n**What's next step** – The success at MNRH shows that hospitals should consider using fast dialysis plans for MALA and similar emergencies. Researchers suggest making dialysis options available quickly to treat patients without delay.\n\n**One-sentence takeaway** – A new quick-start dialysis approach in Thailand significantly lowered deaths from a rare but deadly reaction to a common diabetes drug.\n",
      "personality_title_fr": "Un nouveau protocole de dialyse réduit la mortalité liée à une réaction dangereuse au métformin",
      "personality_presentation_fr": "**Contexte** – Le métformin est un médicament courant pour traiter le diabète de type 2. Rarement, il peut provoquer un problème grave appelé acidose lactique associée au métformin (ALAM), où trop d’acide s’accumule dans le corps. Cette maladie peut être mortelle et nécessite un traitement rapide.\n\n**Ce qui s’est passé** – Un hôpital en Thaïlande, le Maharat Nakhonratchasima Hospital (MNRH), a créé un nouveau protocole pour commencer rapidement la dialyse, un traitement qui enlève l’acide dangereux du sang dès que l’ALAM est diagnostiquée. Ils ont testé ce système pendant cinq ans et ont comparé les résultats avec un autre hôpital qui n’utilisait pas ce protocole.\n\n**Impact** – Ce nouveau protocole a presque réduit de moitié le taux de mortalité à MNRH, passant d’environ 26 % à 14 %. Le traitement a commencé plus vite, avec un gain de près de trois heures entre l’arrivée à l’hôpital et le début de la dialyse. Le personnel médical est aussi devenu beaucoup plus performant pour reconnaître l’ALAM, ce qui a permis de sauver plus de vies.\n\n**Prochaine étape** – Le succès de MNRH montre que les hôpitaux devraient envisager d’utiliser des protocoles rapides de dialyse pour l’ALAM et d’autres urgences similaires. Les chercheurs recommandent de rendre les options de dialyse rapidement disponibles pour traiter les patients sans délai.\n\n**Résumé en une phrase** – Une nouvelle approche de dialyse rapide en Thaïlande a considérablement réduit les décès dus à une réaction rare mais mortelle à un médicament courant contre le diabète.\n",
      "personality_title_es": "Nuevo protocolo de diálisis reduce muertes por reacción peligrosa al metformina",
      "personality_presentation_es": "**Contexto** – La metformina es un medicamento común para tratar la diabetes tipo 2. Raramente, puede causar un problema serio llamado acidosis láctica asociada a la metformina (ALAM), donde se acumula demasiado ácido en el cuerpo. Esta condición puede ser mortal y necesita tratamiento rápido.\n\n**Qué pasó** – Un hospital en Tailandia llamado Maharat Nakhonratchasima Hospital (MNRH) creó un nuevo plan para iniciar rápidamente la diálisis, un tratamiento que elimina el ácido peligroso de la sangre, tan pronto se diagnostica ALAM. Probaron este sistema durante cinco años y compararon los resultados con otro hospital que no usó el nuevo plan.\n\n**Impacto** – El nuevo plan redujo casi a la mitad la tasa de muertes por ALAM en MNRH, bajando de alrededor del 26 % al 14 %. El tratamiento comenzó más rápido, con casi tres horas menos entre la llegada al hospital y el inicio de la diálisis. Los médicos y enfermeros también mejoraron mucho en reconocer ALAM, lo que ayudó a salvar más vidas.\n\n**Próximo paso** – El éxito en MNRH muestra que los hospitales deberían considerar usar planes rápidos de diálisis para ALAM y emergencias similares. Los investigadores sugieren que las opciones de diálisis estén disponibles rápidamente para tratar a los pacientes sin demora.\n\n**Conclusión en una frase** – Un nuevo método de diálisis rápida en Tailandia redujo significativamente las muertes por una reacción rara pero mortal a un medicamento común para la diabetes.\n",
      "image_url": "public/images/news_image_Doctors-found-a-way-to-stop-a-deadly-metformin-rea.png",
      "image_prompt": "A detailed, warm painting of a glowing, stylized kidney shaped like a protective vessel cradling a gentle, translucent blue drop symbolizing metformin, connected by soft flowing lines to a glowing dialysis machine with three distinct, softly illuminated tubes representing the three dialysis methods, all set against a calm, natural color palette that conveys healing and hope."
    },
    {
      "title": "DNA’s hidden power could transform how we make medicines",
      "summary": "Scientists found that DNA’s phosphate groups can direct chemical reactions to make the correct mirror-image form of drug molecules. This breakthrough simplifies chiral drug production, reducing waste and energy use. Using a new “PS scanning” method, the team pinpointed which DNA parts guide reactions. The approach could revolutionize green chemistry in pharmaceuticals.",
      "content": "Researchers at the National University of Singapore (NUS) have uncovered a new way to use deoxyribonucleic acid (DNA). Beyond carrying genetic information, DNA can also serve as a tool for creating medicines more efficiently. Specific regions of DNA known as phosphates act like tiny \"hands\" that guide chemical reactions to form the correct mirror-image version of a compound.\n\nMany medicines are chiral, meaning they exist in two mirror-image forms -- similar to a pair of hands -- that can behave differently inside the body. One version may effectively treat disease, while the other could have little benefit or even cause harm. Producing only the desired form is a major challenge in drug development, but the new DNA-guided method could make this process cleaner, simpler, and more environmentally sustainable.\n\nDNA and proteins naturally attract one another in living cells because DNA's phosphate groups carry a negative charge, while many amino acids are positively charged. The NUS team, led by Assistant Professor Zhu Ru-Yi from the Department of Chemistry, wondered whether this same type of attraction could help control chemical reactions in the lab. Their goal was to see if DNA could guide molecules to react in specific, predictable ways.\n\nHow DNA's Phosphates Guide Chemistry\n\nThe researchers found that certain phosphate groups in DNA can pull in positively charged molecules during a chemical reaction, helping them align correctly -- much like a magnet drawing a metal bead into place. This process, known as \"ion pairing,\" keeps the reacting molecules close together and oriented just right to produce a single, desired mirror-image product. The team showed that this guiding effect works across several different chemical reactions.\n\nTo pinpoint which phosphates were responsible for this guiding ability, the team created a new experimental approach called \"PS scanning.\" They systematically replaced individual phosphate sites in the DNA with nearly identical substitutes and repeated their tests. When swapping out a phosphate reduced the selectivity of the reaction, it revealed that the original site played a crucial role. To confirm their findings, they collaborated with Professor Zhang Xinglong from The Chinese University of Hong Kong, who used computer simulations to validate the experimental results.\n\nThe work was published in Nature Catalysis on October 31, 2025.\n\nDNA as a Green Chemistry Tool\n\nAsst Prof Zhu explained, \"Nature never uses DNA phosphates as catalysts, but we have shown that if designed properly, they can act like artificial enzymes.\"\n\nHe added that the discovery could make chemical manufacturing both more sustainable and more efficient, especially when producing complex, high-value pharmaceuticals.\n\nThe team plans to continue exploring how DNA phosphates can be used to design and produce chiral (mirror-image) compounds for next-generation drug development.",
      "url": "https://www.sciencedaily.com/releases/2025/11/251108083914.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-11-09",
      "sentiment_score": 0.9,
      "reasoning": "The article reports a significant scientific breakthrough where DNA’s phosphate groups are used to guide chemical reactions to produce the correct mirror-image forms of drug molecules. This innovation promises to simplify chiral drug production, reduce waste and energy use, and promote greener pharmaceutical manufacturing. The discovery has broad implications for medicine production and environmental sustainability, with detailed context and experimental validation provided.",
      "category": "Health",
      "personality_title": "DNA’s phosphate groups guide cleaner drug production",
      "personality_presentation": "**Context** – Scientists have long known DNA carries genetic information, but now researchers at the National University of Singapore found its phosphate parts can help make medicines. Many drugs come in two mirror-image forms, but only one form works well and is safe. Making just the right form is often difficult and wasteful.\n\n**What happened** – The NUS team discovered that DNA’s phosphate groups act like tiny magnets, pulling molecules into the right position during chemical reactions to produce the correct mirror-image drug form. They developed a new method called “PS scanning” to identify which phosphate parts guide these reactions. Their findings were supported by computer simulations and published in Nature Catalysis in October 2025.\n\n**Impact** – This discovery means drug makers can use DNA to control how medicines are made, making the process cleaner and more energy-efficient. It could reduce waste and help produce safer medicines faster. Using DNA’s natural properties in this new way is a step toward greener chemistry in the pharmaceutical industry.\n\n**What's next step** – The researchers plan to explore more uses of DNA phosphates to design and produce other mirror-image drug molecules. This may lead to better methods for creating complex medicines with less environmental impact.\n\n**One-sentence takeaway** – Scientists found DNA’s phosphate groups can guide chemical reactions to make safer, cleaner medicines by producing the correct mirror-image drug forms.",
      "personality_title_fr": "Les groupes phosphate de l’ADN facilitent une production plus propre de médicaments",
      "personality_presentation_fr": "**Contexte** – On sait depuis longtemps que l’ADN porte l’information génétique, mais des chercheurs de l’Université nationale de Singapour ont découvert que ses groupes phosphate peuvent aider à fabriquer des médicaments. Beaucoup de médicaments existent en deux formes miroir, mais une seule forme est efficace et sûre. Produire uniquement la bonne forme est souvent difficile et génère des déchets.\n\n**Ce qui s’est passé** – L’équipe de l’UNS a découvert que les groupes phosphate de l’ADN agissent comme de petits aimants, attirant les molécules dans la bonne position lors des réactions chimiques pour obtenir la forme miroir correcte du médicament. Ils ont créé une méthode appelée « PS scanning » pour identifier quelles parties phosphate guident ces réactions. Leurs résultats, soutenus par des simulations informatiques, ont été publiés dans Nature Catalysis en octobre 2025.\n\n**Impact** – Cette découverte signifie que les fabricants de médicaments peuvent utiliser l’ADN pour contrôler la fabrication, rendant le processus plus propre et économe en énergie. Cela pourrait réduire les déchets et accélérer la production de médicaments plus sûrs. Utiliser ainsi les propriétés naturelles de l’ADN est un pas vers une chimie plus verte dans l’industrie pharmaceutique.\n\n**Prochaine étape** – Les chercheurs prévoient d’explorer d’autres usages des phosphates de l’ADN pour concevoir et produire d’autres molécules médicamenteuses en forme miroir. Cela pourrait mener à de meilleures méthodes pour créer des médicaments complexes avec moins d’impact environnemental.\n\n**Résumé en une phrase** – Les scientifiques ont découvert que les groupes phosphate de l’ADN peuvent guider les réactions chimiques pour fabriquer des médicaments plus sûrs et plus propres en produisant la bonne forme miroir.",
      "personality_title_es": "Los grupos fosfato del ADN guían una producción de medicamentos más limpia",
      "personality_presentation_es": "**Contexto** – Se sabe que el ADN contiene la información genética, pero investigadores de la Universidad Nacional de Singapur descubrieron que sus grupos fosfato pueden ayudar a fabricar medicamentos. Muchos fármacos existen en dos formas espejo, pero solo una es efectiva y segura. Producir solo la forma correcta suele ser difícil y generar desperdicio.\n\n**Qué pasó** – El equipo de la NUS encontró que los grupos fosfato del ADN actúan como pequeños imanes, atrayendo moléculas a la posición correcta durante las reacciones químicas para crear la forma espejo adecuada del medicamento. Crearon un método llamado “PS scanning” para identificar qué partes fosfato guían estas reacciones. Sus resultados, apoyados por simulaciones por computadora, fueron publicados en Nature Catalysis en octubre de 2025.\n\n**Impacto** – Este descubrimiento significa que los fabricantes de medicamentos pueden usar el ADN para controlar la producción, haciendo el proceso más limpio y eficiente en energía. Esto podría reducir desperdicios y acelerar la fabricación de medicamentos más seguros. Usar las propiedades naturales del ADN de esta manera es un avance hacia una química más verde en la industria farmacéutica.\n\n**Próximo paso** – Los investigadores planean explorar más usos de los fosfatos del ADN para diseñar y producir otras moléculas de medicamentos en forma espejo. Esto podría llevar a mejores métodos para crear medicamentos complejos con menor impacto ambiental.\n\n**Resumen en una frase** – Los científicos descubrieron que los grupos fosfato del ADN pueden guiar reacciones químicas para fabricar medicamentos más seguros y limpios al producir la forma espejo correcta.",
      "image_url": "public/images/news_image_DNAs-hidden-power-could-transform-how-we-make-medi.png",
      "image_prompt": "A warm, detailed painting of intertwined DNA strands glowing softly with highlighted phosphate groups shaped like delicate, guiding hands gently steering shining, mirror-image molecular structures into perfect alignment, set against a simple, natural-toned background symbolizing harmony and sustainable innovation."
    }
  ]
}